Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC.CBIO · Entity 5255 | President and COO | September 16, 2026 | September 18, 2026 |
| Dyne Therapeutics, Inc.DYN · Entity 3948 | Chief Business Officer | August 19, 2024 | August 20, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CRESCENT BIOPHARMA, INC.
Report date September 16, 2026 · Filed September 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 134,588 |
Ending reported balance
After 2026-09-18 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-16 · Sale · Disposed 731 · Balance 138,427 F1: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025 and March 17, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on February 25, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F2: The prices reported in Column 4 are weighted average prices. These shares were sold in multiple transactions at prices ranging from $17.10 to $19.17 on September 16, 2026 and from $16.15 to $17.23 on September 18, 2026, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Row 2 · 2026-09-18 · Sale · Disposed 3,839 · Balance 134,588 F1: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025 and March 17, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on February 25, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F2: The prices reported in Column 4 are weighted average prices. These shares were sold in multiple transactions at prices ranging from $17.10 to $19.17 on September 16, 2026 and from $16.15 to $17.23 on September 18, 2026, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025 and March 17, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on February 25, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
F2: The prices reported in Column 4 are weighted average prices. These shares were sold in multiple transactions at prices ranging from $17.10 to $19.17 on September 16, 2026 and from $16.15 to $17.23 on September 18, 2026, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
Dyne Therapeutics, Inc.
Report date August 19, 2024 · Filed August 20, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 132,411 |
Reported balance
After 2024-08-19 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-08-19 · Sale · Disposed 2,400 · Balance 132,411 F1: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on January 25, 2024 and the sale does not represent a discretionary trade by the Reporting Person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $44.51 to $45.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes of this Form 4. |
| Common StockSEC Table I · non-derivative | Direct | 132,106 |
Reported balance
After 2024-08-19 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2024-08-19 · Sale · Disposed 305 · Balance 132,106 F1: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on January 25, 2024 and the sale does not represent a discretionary trade by the Reporting Person. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $45.53 to $46.45, inclusive. F4: Includes 116,875 unvested RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on January 25, 2024 and the sale does not represent a discretionary trade by the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $44.51 to $45.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes of this Form 4.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $45.53 to $46.45, inclusive.
F4: Includes 116,875 unvested RSUs.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 18, 2026 Filed Sep 18, 2026 20:01 UTC | CRESCENT BIOPHARMA, INC. CBIO · Entity 5255 | SaleOrdinary Shares | 3,839 | $16.71 | $64,149.69 |
DisclosureSEC source: 0001628280-26-062700 · wk-form4_1789761701.xml · nonDerivative · entry 2 McNeill Jonathan · CIK 0001824673 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 134,588 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025 and March 17, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on February 25, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F2 · price: The prices reported in Column 4 are weighted average prices. These shares were sold in multiple transactions at prices ranging from $17.10 to $19.17 on September 16, 2026 and from $16.15 to $17.23 on September 18, 2026, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| September 16, 2026 Filed Sep 18, 2026 20:01 UTC | CRESCENT BIOPHARMA, INC. CBIO · Entity 5255 | SaleOrdinary Shares | 731 | $17.90 | $13,084.90 |
DisclosureSEC source: 0001628280-26-062700 · wk-form4_1789761701.xml · nonDerivative · entry 1 McNeill Jonathan · CIK 0001824673 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 138,427 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025 and March 17, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on February 25, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F2 · price: The prices reported in Column 4 are weighted average prices. These shares were sold in multiple transactions at prices ranging from $17.10 to $19.17 on September 16, 2026 and from $16.15 to $17.23 on September 18, 2026, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| June 22, 2026 Filed Jun 23, 2026 20:02 UTC | CRESCENT BIOPHARMA, INC. CBIO · Entity 5255 | SaleOrdinary Shares | 20,549 | $17.99 | $369,676.51 |
DisclosureSEC source: 0001628280-26-044885 · wk-form4_1782244938.xml · nonDerivative · entry 1 McNeill Jonathan · CIK 0001824673 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 139,158 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025 and March 17, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on February 25, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.88 to $18.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 21:43 UTC | CRESCENT BIOPHARMA, INC. CBIO · Entity 5255 | GrantStock Option (Right to Buy) · Derivative | 78,029 | $0.00 Strike: $13.21 | $0.00 |
DisclosureSEC source: 0001628280-25-057678 · wk-form4_1766007778.xml · derivative · entry 3 McNeill Jonathan · CIK 0001824673 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,029 Underlying: Ordinary Shares · 78,029 shares Expires 2035-12-15 F2 · derivative.exercise_date: This Option represents a right to purchase shares of the Issuer's Ordinary Shares and vests with respect to 1/48th of the Option on each monthly anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 21:43 UTC | CRESCENT BIOPHARMA, INC. CBIO · Entity 5255 | GrantOrdinary Shares | 6,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-057678 · wk-form4_1766007778.xml · nonDerivative · entry 2 McNeill Jonathan · CIK 0001824673 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 159,707 F1 · price: Represents an award of Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Ordinary Shares. The RSUs shall vest in approximately equal three-month installments through the four-year anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 21:43 UTC | CRESCENT BIOPHARMA, INC. CBIO · Entity 5255 | GrantOrdinary Shares | 19,507 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-057678 · wk-form4_1766007778.xml · nonDerivative · entry 1 McNeill Jonathan · CIK 0001824673 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,707 F1 · price: Represents an award of Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Ordinary Shares. The RSUs shall vest in approximately equal three-month installments through the four-year anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 21:37 UTC | CRESCENT BIOPHARMA, INC. CBIO · Entity 5255 | GrantStock Option (Right to Buy) · Derivative | 172,836 | $0.00 Strike: $13.17 | $0.00 |
DisclosureSEC source: 0001628280-25-056333 · wk-form4_1765402643.xml · derivative · entry 1 McNeill Jonathan · CIK 0001824673 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 172,836 Underlying: Ordinary Shares · 172,836 shares Expires 2035-12-08 F1 · derivative.exercise_date: This option represents a right to purchase shares of the Issuer's ordinary shares and vests in 48 approximately equal monthly installments that commenced on December 8, 2025. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 20:27 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 305 | $46.00 | $14,030.00 |
DisclosureSEC source: 0000950170-24-099127 · ownership.xml · nonDerivative · entry 2 McNeill Jonathan · CIK 0001824673 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 132,106 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on January 25, 2024 and the sale does not represent a discretionary trade by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $45.53 to $46.45, inclusive. F4 · balance_after: Includes 116,875 unvested RSUs. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 20:27 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 2,400 | $45.01 | $108,024.00 |
DisclosureSEC source: 0000950170-24-099127 · ownership.xml · nonDerivative · entry 1 McNeill Jonathan · CIK 0001824673 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 132,411 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on January 25, 2024 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $44.51 to $45.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes of this Form 4. Read SEC document |
| June 11, 2024 Filed Jun 11, 2024 23:34 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 1,823 | $31.34 | $57,132.82 |
DisclosureSEC source: 0000950170-24-072151 · ownership.xml · nonDerivative · entry 1 McNeill Jonathan · CIK 0001824673 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,811 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $31.00 to $31.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · balance_after: Includes 122,885 unvested RSUs. Read SEC document |
| May 16, 2024 Filed May 18, 2024 01:03 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 495 | $28.59 | $14,152.05 |
DisclosureSEC source: 0000950170-24-062075 · ownership.xml · nonDerivative · entry 2 McNeill Jonathan · CIK 0001824673 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 136,634 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on January 25, 2024 and the sale does not represent a discretionary trade by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $28.51 to $28.70, inclusive. F4 · balance_after: Includes 126,967 unvested RSUs. Read SEC document |
| May 16, 2024 Filed May 18, 2024 01:03 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 2,279 | $28.20 | $64,267.80 |
DisclosureSEC source: 0000950170-24-062075 · ownership.xml · nonDerivative · entry 1 McNeill Jonathan · CIK 0001824673 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 137,129 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on January 25, 2024 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.50 to $28.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes of this Form 4. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 10:04 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionStock option (right to buy) · Derivative | 17,825 | $0.00 Strike: $5.54 | $0.00 |
DisclosureSEC source: 0000950170-24-030484 · ownership.xml · derivative · entry 11 McNeill Jonathan · CIK 0001824673 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,825 shares Expires 2030-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an IND application submitted to the FDA by the Company with respect to one ofitsproduct candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined thattheperformance condition had been achieved. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 10:04 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 1,776 | $25.71 | $45,660.96 |
DisclosureSEC source: 0000950170-24-030484 · ownership.xml · nonDerivative · entry 8 McNeill Jonathan · CIK 0001824673 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 139,408 F5 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.67 to $25.81, inclusive. F7 · balance_after: Includes 132,976 unvested RSUs. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 10:04 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 17,825 | $25.48 | $454,181.00 |
DisclosureSEC source: 0000950170-24-030484 · ownership.xml · nonDerivative · entry 7 McNeill Jonathan · CIK 0001824673 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 141,184 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.14 to $26.09, inclusive. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 10:04 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionCommon Stock | 17,825 | $5.54 | $98,750.50 |
DisclosureSEC source: 0000950170-24-030484 · ownership.xml · nonDerivative · entry 6 McNeill Jonathan · CIK 0001824673 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 159,009 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 08, 2024 Filed Mar 13, 2024 10:04 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionStock option (right to buy) · Derivative | 3,841 | $0.00 Strike: $5.54 | $0.00 |
DisclosureSEC source: 0000950170-24-030484 · ownership.xml · derivative · entry 10 McNeill Jonathan · CIK 0001824673 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · 3,841 shares Expires 2030-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an IND application submitted to the FDA by the Company with respect to one ofitsproduct candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined thattheperformance condition had been achieved. Read SEC document |
| March 08, 2024 Filed Mar 13, 2024 10:04 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionStock option (right to buy) · Derivative | 86,159 | $0.00 Strike: $5.54 | $0.00 |
DisclosureSEC source: 0000950170-24-030484 · ownership.xml · derivative · entry 9 McNeill Jonathan · CIK 0001824673 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,309 Underlying: Common Stock · 86,159 shares Expires 2030-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option was granted on July 31, 2020. The shares underlying the option vest over four years in equal quarterly installments beginning on October 31, 2020. Read SEC document |
| March 08, 2024 Filed Mar 13, 2024 10:04 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 689 | $27.31 | $18,816.59 |
DisclosureSEC source: 0000950170-24-030484 · ownership.xml · nonDerivative · entry 5 McNeill Jonathan · CIK 0001824673 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 141,184 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.27 to $27.39, inclusive. Read SEC document |
| March 08, 2024 Filed Mar 13, 2024 10:04 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 54,648 | $26.72 | $1,460,194.56 |
DisclosureSEC source: 0000950170-24-030484 · ownership.xml · nonDerivative · entry 4 McNeill Jonathan · CIK 0001824673 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 141,873 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.25 to $27.19, inclusive. Read SEC document |
| March 08, 2024 Filed Mar 13, 2024 10:04 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 34,663 | $25.46 | $882,519.98 |
DisclosureSEC source: 0000950170-24-030484 · ownership.xml · nonDerivative · entry 3 McNeill Jonathan · CIK 0001824673 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 196,521 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.25 to $26.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| March 08, 2024 Filed Mar 13, 2024 10:04 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionCommon Stock | 3,841 | $5.54 | $21,279.14 |
DisclosureSEC source: 0000950170-24-030484 · ownership.xml · nonDerivative · entry 2 McNeill Jonathan · CIK 0001824673 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 231,184 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.25 to $26.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| March 08, 2024 Filed Mar 13, 2024 10:04 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionCommon Stock | 86,159 | $5.54 | $477,320.86 |
DisclosureSEC source: 0000950170-24-030484 · ownership.xml · nonDerivative · entry 1 McNeill Jonathan · CIK 0001824673 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 227,343 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 07, 2024 Filed Mar 12, 2024 01:50 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 2,434 | $25.85 | $62,918.90 |
DisclosureSEC source: 0000950170-24-029607 · ownership.xml · nonDerivative · entry 1 McNeill Jonathan · CIK 0001824673 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 141,184 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.84 to $26.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · balance_after: Includes 137,058 unvested RSUs. Read SEC document |
| March 01, 2024 Filed Mar 2, 2024 02:37 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionStock option (right to buy) · Derivative | 24,260 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0000950170-24-024299 · ownership.xml · derivative · entry 8 McNeill Jonathan · CIK 0001824673 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,260 shares Expires 2029-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option was granted on February 26, 2019. The shares underlying the option vest over four years, with 25% of the shares vesting on February 1, 2020 and the remaining shares vesting in equal quarterly installments thereafter. Read SEC document |
| March 01, 2024 Filed Mar 2, 2024 02:37 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 1,442 | $29.70 | $42,827.40 |
DisclosureSEC source: 0000950170-24-024299 · ownership.xml · nonDerivative · entry 6 McNeill Jonathan · CIK 0001824673 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 143,618 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $29.58 to $29.88, inclusive. F1 · balance_after: Includes 137,058 unvested RSUs. Read SEC document |
| March 01, 2024 Filed Mar 2, 2024 02:37 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 8,715 | $29.06 | $253,257.90 |
DisclosureSEC source: 0000950170-24-024299 · ownership.xml · nonDerivative · entry 5 McNeill Jonathan · CIK 0001824673 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 145,060 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $28.56 to $29.51, inclusive. F1 · balance_after: Includes 137,058 unvested RSUs. Read SEC document |
| March 01, 2024 Filed Mar 2, 2024 02:37 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 14,103 | $28.25 | $398,409.75 |
DisclosureSEC source: 0000950170-24-024299 · ownership.xml · nonDerivative · entry 4 McNeill Jonathan · CIK 0001824673 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 153,775 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.50 to $28.48, inclusive. F1 · balance_after: Includes 137,058 unvested RSUs. Read SEC document |
| March 01, 2024 Filed Mar 2, 2024 02:37 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionCommon Stock | 24,260 | $0.73 | $17,709.80 |
DisclosureSEC source: 0000950170-24-024299 · ownership.xml · nonDerivative · entry 3 McNeill Jonathan · CIK 0001824673 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 167,878 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 137,058 unvested RSUs. Read SEC document |
| February 29, 2024 Filed Mar 2, 2024 02:37 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionStock option (right to buy) · Derivative | 4,268 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0000950170-24-024299 · ownership.xml · derivative · entry 7 McNeill Jonathan · CIK 0001824673 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,260 Underlying: Common Stock · 4,268 shares Expires 2029-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option was granted on February 26, 2019. The shares underlying the option vest over four years, with 25% of the shares vesting on February 1, 2020 and the remaining shares vesting in equal quarterly installments thereafter. Read SEC document |
| February 29, 2024 Filed Mar 2, 2024 02:37 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 4,268 | $27.50 | $117,370.00 |
DisclosureSEC source: 0000950170-24-024299 · ownership.xml · nonDerivative · entry 2 McNeill Jonathan · CIK 0001824673 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 143,618 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.50 to $27.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes of this Form 4. F1 · balance_after: Includes 137,058 unvested RSUs. Read SEC document |
| February 29, 2024 Filed Mar 2, 2024 02:37 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionCommon Stock | 4,268 | $0.73 | $3,115.64 |
DisclosureSEC source: 0000950170-24-024299 · ownership.xml · nonDerivative · entry 1 McNeill Jonathan · CIK 0001824673 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 147,886 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 137,058 unvested RSUs. Read SEC document |
| January 26, 2024 Filed Jan 27, 2024 00:48 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0000950170-24-008062 · ownership.xml · derivative · entry 4 McNeill Jonathan · CIK 0001824673 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,528 Underlying: Common Stock · 20,000 shares Expires 2029-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option was granted on February 26, 2019. The shares underlying the option vest over four years, with 25% of the shares vesting on February 1, 2020 and the remaining shares vesting in equal quarterly installments thereafter. Read SEC document |
| January 26, 2024 Filed Jan 27, 2024 00:48 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 178 | $25.14 | $4,474.92 |
DisclosureSEC source: 0000950170-24-008062 · ownership.xml · nonDerivative · entry 3 McNeill Jonathan · CIK 0001824673 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 143,618 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.01 to $25.25, inclusive. F1 · balance_after: Includes 143,067 unvested RSUs. Read SEC document |
| January 26, 2024 Filed Jan 27, 2024 00:48 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 19,822 | $24.52 | $486,035.44 |
DisclosureSEC source: 0000950170-24-008062 · ownership.xml · nonDerivative · entry 2 McNeill Jonathan · CIK 0001824673 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 143,796 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $24.00 to $24.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes of this Form 4. F1 · balance_after: Includes 143,067 unvested RSUs. Read SEC document |
| January 26, 2024 Filed Jan 27, 2024 00:48 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionCommon Stock | 20,000 | $0.73 | $14,600.00 |
DisclosureSEC source: 0000950170-24-008062 · ownership.xml · nonDerivative · entry 1 McNeill Jonathan · CIK 0001824673 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 163,618 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 143,067 unvested RSUs. Read SEC document |
| January 04, 2024 Filed Jan 5, 2024 02:47 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionStock option (right to buy) · Derivative | 2,009 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0000950170-24-002278 · ownership.xml · derivative · entry 8 McNeill Jonathan · CIK 0001824673 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,528 Underlying: Common Stock · 2,009 shares Expires 2029-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option was granted on February 26, 2019. The shares underlying the option vest over four years, with 25% of the shares vesting on February 1, 2020 and the remaining shares vesting in equal quarterly installments thereafter. Read SEC document |
| January 04, 2024 Filed Jan 5, 2024 02:47 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 2,009 | $18.04 | $36,242.36 |
DisclosureSEC source: 0000950170-24-002278 · ownership.xml · nonDerivative · entry 6 McNeill Jonathan · CIK 0001824673 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 143,618 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.00 to $18.07, inclusive. F3 · balance_after: Includes 143,067 unvested RSUs. Read SEC document |
| January 04, 2024 Filed Jan 5, 2024 02:47 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionCommon Stock | 2,009 | $0.73 | $1,466.57 |
DisclosureSEC source: 0000950170-24-002278 · ownership.xml · nonDerivative · entry 5 McNeill Jonathan · CIK 0001824673 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 145,627 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · balance_after: Includes 143,067 unvested RSUs. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 02:47 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionStock option (right to buy) · Derivative | 17,991 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0000950170-24-002278 · ownership.xml · derivative · entry 7 McNeill Jonathan · CIK 0001824673 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,537 Underlying: Common Stock · 17,991 shares Expires 2029-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option was granted on February 26, 2019. The shares underlying the option vest over four years, with 25% of the shares vesting on February 1, 2020 and the remaining shares vesting in equal quarterly installments thereafter. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 02:47 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 10,300 | $19.03 | $196,009.00 |
DisclosureSEC source: 0000950170-24-002278 · ownership.xml · nonDerivative · entry 4 McNeill Jonathan · CIK 0001824673 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 143,618 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $19.00 to $19.25, inclusive. F3 · balance_after: Includes 143,067 unvested RSUs. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 02:47 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 7,691 | $18.34 | $141,052.94 |
DisclosureSEC source: 0000950170-24-002278 · ownership.xml · nonDerivative · entry 3 McNeill Jonathan · CIK 0001824673 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 153,918 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.00 to $18.50, inclusive. F3 · balance_after: Includes 143,067 unvested RSUs. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 02:47 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionCommon Stock | 17,991 | $0.73 | $13,133.43 |
DisclosureSEC source: 0000950170-24-002278 · ownership.xml · nonDerivative · entry 2 McNeill Jonathan · CIK 0001824673 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 161,609 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · balance_after: Includes 143,067 unvested RSUs. Read SEC document |
| January 02, 2024 Filed Jan 5, 2024 02:47 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 11,900 | $13.10 | $155,890.00 |
DisclosureSEC source: 0000950170-24-002278 · ownership.xml · nonDerivative · entry 1 McNeill Jonathan · CIK 0001824673 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 143,618 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $12.76 to $13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes of this Form 4. F3 · balance_after: Includes 143,067 unvested RSUs. Read SEC document |
| December 11, 2023 Filed Dec 12, 2023 22:34 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 1,245 | $10.72 | $13,346.40 |
DisclosureSEC source: 0001209191-23-058330 · doc4.xml · nonDerivative · entry 1 McNeill Jonathan · CIK 0001824673 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,518 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $10.72 to $10.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · balance_after: Includes 143,067 unvested RSUs. Read SEC document |
| November 15, 2023 Filed Nov 16, 2023 21:34 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantStock Option (right to buy) · Derivative | 37,445 | $0.00 Strike: $10.88 | $0.00 |
DisclosureSEC source: 0001209191-23-055530 · doc4.xml · derivative · entry 2 McNeill Jonathan · CIK 0001824673 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,445 Underlying: Common Stock · 37,445 shares Expires 2033-11-14 F3 · derivative.exercise_date: This option was granted on November 15, 2023. The shares underlying the option are scheduled to vest over four years in equal monthly installments through November 15, 2027. Read SEC document |
| November 15, 2023 Filed Nov 16, 2023 21:34 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantCommon Stock | 96,158 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-055530 · doc4.xml · nonDerivative · entry 1 McNeill Jonathan · CIK 0001824673 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,763 F1 · shares: Consists of shares of Common Stock issuable under 96,158 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on February 15, 2024. F2 · balance_after: Includes 147,149 unvested RSUs. Read SEC document |
| September 18, 2023 Filed Sep 20, 2023 20:49 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 1,261 | $9.41 | $11,866.01 |
DisclosureSEC source: 0001209191-23-050173 · doc4.xml · nonDerivative · entry 1 McNeill Jonathan · CIK 0001824673 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,605 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 17, 2020. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · balance_after: Includes 50,991 unvested RSUs. Read SEC document |
| September 12, 2023 Filed Sep 13, 2023 23:53 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 1,266 | $10.41 | $13,179.06 |
DisclosureSEC source: 0001209191-23-049360 · doc4.xml · nonDerivative · entry 1 McNeill Jonathan · CIK 0001824673 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,866 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $10.08 to $10.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4. F2 · balance_after: Includes 55,244 unvested RSUs. Read SEC document |
| July 11, 2023 Filed Apr 5, 2024 01:06 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantStock option (right to buy) · Derivative | 35,000 | $0.00 Strike: $11.79 | $0.00 |
DisclosureSEC source: 0000950170-24-042032 · ownership.xml · derivative · entry 1 McNeill Jonathan · CIK 0001824673 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2033-07-10 F1 · date: This transaction is being reported late due to an inadvertent administrative error. F2 · derivative.exercise_date: This option award was granted on July 11, 2023 and vests over four years in equal monthly installments, with the first vesting occurring on August 1, 2023 and the remaining vesting occurring each month subsequent to the first vesting date, subject to continuous service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.